Speeding biologics R&D with software, data flows
Biologics are changing the way we treat disease, affecting where companies invest and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by the Center for Drug Evaluation and Research (CDER) were biologics, while its partner agency — the Center for Biologics Evaluation and Research (CBER) — approved a
